Steatohepatitis/Metabolic Liver Disease News

Alcohol use disorder has a huge impact on liver health. Regardless of whether patients have other primary etiology for liver disease, alcohol — even in minimal amounts — can worsen liver outcomes.

Adherence to treatment with glucagon-like peptide-1 receptor agonists may lower the long-term risk for major adverse liver outcomes among patients with chronic liver disease and type 2 diabetes, according to data in Gut.

The FDA has granted 510(k) clearance to Nanox’s HealthFLD artificial intelligence software to aid clinicians in the detection of fatty liver associated with hepatic steatosis, according to a company press release.

Individuals with alcohol-related liver disease and frequent health care utilization were at greater risk for mortality and hospital readmission, respectively, according to a cohort study of alcohol-related hospitalizations in Canada.

Women with concurrent metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease had an 83% greater risk for all-cause mortality than men and those with ALD alone had 160% greater risk, data showed.

Chronic hepatitis B virus infection was positively linked with severe hepatic necroinflammation in children with metabolic dysfunction-associated steatotic liver disease but did not appear to affect hepatic fibrosis, according to data.

Atopic dermatitis in children may be associated with metabolic syndrome and nonalcoholic fatty liver disease, according to a study.

Topline data from the phase 2b FASCINATE-2 trial showed “statistically significant improvement” for denifanstat in biopsy-confirmed nonalcoholic steatohepatitis with stage 2 or stage 3 fibrosis at 52 weeks, Sagimet Biosciences announced.

Screening for liver fibrosis was associated with improved self-reported alcohol consumption, diet, exercise and weight after 6 months among patients at risk for liver disease, with lifestyle changes persisting through 2 years.

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.